MEILISA SRI SUZANA

H1AP10026

TUGAS EVIDENCE BASED CASE REPORT

P (Population)

: Paediatrics with Candidiasis

I (Intervention) : Fluconazole
C (Comparison) : Other Anti Fungal, Placebo, Nystatin
O (Outcome)

: Side effect of use fluconazole

Critical Appraisal
A. First acronym: PECOT

90 study
( 4.209 Patiens )

Participants

ECO
Fluconazole with

GI Events
( P Value )
0, 235
0,831
0,219

Other Antifungal
Placebo
Nystatin

Hepatotoxity Mortality
( P Value )
( P Value )
0,352
0,960
0,175
0,067
0,016
0,825

Withdrawal due to AE
( P Value )
0,534
0, 828
0,992

Time: 25 years
B. RAMBOMAN
a.
b.
c.
d.
e.

a.
b.
c.
d.

1. Recruitment
:
Paediatric age groups of preterm neonates (<36 weeks
gestation, 027 days)
Full-term neonates (027 days, >37 weeks gesta- tion)
Infants and toddlers (28 days23 months)
Children (211 years
Adolescents (1217 years).

2. Allocated :
Side Effect of fluconazole exposed
a. Hepatotoxity most common cause Fluconazole combine with
other antifungal
b. GI event most common cause Fluconazole combine with Placebo
c. Mortality most common cause Fluconazole combine with other
antifungal
d. Withdrawal due to AE most common cause Fluconazole combine
with Nystatin
3. Maintained:
Completeness : Compliance : Contamination : Co-interventions : -

4. Blind

:-

5. Objective measured : 6. Analyzed:

o Meta analysis was perfomed using the Stata/IC v.11 statistical package
o The Mantel and Haenszel method
o The DerSimorian and Lairds Q Statistic
o Chi-Square
o The Q Statistic
o The I2 Statistic